Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
Investors will be hoping for strength from AZN as it approaches its next earnings release. Meanwhile, our latest consensus estimate is calling for revenue of $6.66 billion, up 3.92% from the prior-year quarter. For the full year, our Zacks Consensus Estimates are projecting earnings of $2.03 per share and revenue of $26.26 billion, which would represent changes of +16% and +7.69%, respectively, from the prior year. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Its industry sports an average Forward P/E of 14.57, so we one might conclude that AZN is trading at a premium comparatively.